Detailed Information

Cited 7 time in webofscience Cited 6 time in scopus
Metadata Downloads

Enhanced Systemic Anti-Angiogenic siVEGF Delivery Using PEGylated Oligo-D-arginine

Full metadata record
DC Field Value Language
dc.contributor.authorChung, Jee Young-
dc.contributor.authorUl Ain, Qurrat-
dc.contributor.authorLee, Hyun Lin-
dc.contributor.authorKim, So-Mi-
dc.contributor.authorKim, Yong-Hee-
dc.date.accessioned2021-07-30T05:33:12Z-
dc.date.available2021-07-30T05:33:12Z-
dc.date.issued2017-09-
dc.identifier.issn1543-8384-
dc.identifier.issn1543-8392-
dc.identifier.urihttps://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5382-
dc.description.abstractAngiogenesis mainly mediated by upregulation of vascular endothelial growth factor (VEGF) provides a hallmark of rapidly proliferating tumor cells and an essential component of the tumor growth and microenvironment, making it a targetable process for antitumor therapy. RNA interference (RNAi) provides a very effective tool for developing antitumor therapies; however, its application to date has been hampered due to the lack of efficient small interfering RNA (siRNA) delivery systems in vivo. Here, we report a polymeric gene carrier system based on PEGylation of a cationic cysteine-ended 9-mer arginine oligopeptide (CR9C), which provides effective siRNA systemic delivery and specifically suppresses VEGF (siVEGF). The PEG500-CR9C/siVEGF oligopeptoplex provided improved blood circulation, enhanced protection from serum proteases, reduced uptake in the liver and kidneys, enhanced tumor targeting, and down-regulated intratumoral VEGF level, which comprehensively resulted in improved antitumor efficacy without significant toxicity in vivo. PEG500-CR9C has a great potential for safe and efficient siRNA delivery with diverse applications.-
dc.format.extent10-
dc.language영어-
dc.language.isoENG-
dc.publisherAmerican Chemical Society-
dc.titleEnhanced Systemic Anti-Angiogenic siVEGF Delivery Using PEGylated Oligo-D-arginine-
dc.typeArticle-
dc.publisher.location미국-
dc.identifier.doi10.1021/acs.molpharmaceut.7b00282-
dc.identifier.scopusid2-s2.0-85028817161-
dc.identifier.wosid000410005100019-
dc.identifier.bibliographicCitationMolecular Pharmaceutics, v.14, no.9, pp 3059 - 3068-
dc.citation.titleMolecular Pharmaceutics-
dc.citation.volume14-
dc.citation.number9-
dc.citation.startPage3059-
dc.citation.endPage3068-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaResearch & Experimental Medicine-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalWebOfScienceCategoryMedicine, Research & Experimental-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.subject.keywordPlusSMALL-INTERFERING RNA-
dc.subject.keywordPlusSIRNA DELIVERY-
dc.subject.keywordPlusGENE DELIVERY-
dc.subject.keywordPlusIN-VIVO-
dc.subject.keywordPlusCANCER-THERAPY-
dc.subject.keywordPlusPEPTIDE-
dc.subject.keywordPlusNANOPARTICLES-
dc.subject.keywordPlusCIRCULATION-
dc.subject.keywordPlusPOLYPLEXES-
dc.subject.keywordPlusCARRIER-
dc.subject.keywordAuthorangiogenesis-
dc.subject.keywordAuthorenhanced permeability and enhanced effect-
dc.subject.keywordAuthorsiVEGF delivery-
dc.subject.keywordAuthorPEGylation-
dc.subject.keywordAuthorantitumor therapy-
dc.identifier.urlhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.7b00282-
Files in This Item
Go to Link
Appears in
Collections
서울 공과대학 > 서울 생명공학과 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE